| アブストラクト | An evaluation of the US Food and Drug Administration's Adverse Event Reporting System identified that patients coinfected with human immunodeficiency virus and chronic hepatitis C virus who were treated with a regimen of ribavirin and didanosine, with or without stavudine, were at increased risk for events associated with mitochondrial toxicity, including fatal hepatic failure, peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis. In response, the US product labels for didanosine and ribavirin have been revised to caution clinicians against coadministration of these drugs. |
|---|
| ジャーナル名 | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
|---|
| Pubmed追加日 | 2004/04/20 |
|---|
| 投稿者 | Fleischer, Russell; Boxwell, Debra; Sherman, Kenneth E |
|---|
| 組織名 | Division of Antiviral Drug Products, Center for Drug Evaluation and Research,;Food and Drug Administration, Rockville, Maryland 20857, USA.;fleischerr@cder.fda.gov |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/15095236/ |
|---|
